TBTatiana A. Bakhareva

Tatiana A. Bakhareva

*This is an algorithmically generated author record based on publicly available information.

Tatiana A. Bakhareva has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Polysomnographic characteristics of obstructive sleep apnea in obese patients

    by T. A. Bakhareva, A. M. Belov, I. A. Baranova, Т. А. Бахарева, А. М. Белов, И. А. Баранова

    The available scientific research does not sufficiently describe the specific polysomnographic (PSG) characteristics of obstructive sleep apnea (OSA) in obese patients. The aim was to determine the clinical and PSG characteristics of OSA in obese patients. Methods . The study included retrospective analysis of medical histories, assessment of the frequency of concomitant and previous diseases, and analysis of PSG results (Сomet PSG, Grass Technologies, USA). Results . The study included 2 groups of patients: the main group with OSA and BMI > 30 kg/m2 (n = 100) and the control group with OSA and BMI 18 – 25 kg/m2 (n = 44). In the main group, the Charlson comorbidity index (p = 0.012), the likelihood of hypertension (OR 6.4 (95% CI 2.9 – 14.2)), type 2 diabetes mellitus or impaired glucose tolerance (OR 29.9 (95% CI 3.9 – 225.7)), dyslipidemia (OR 2.4 (95% CI 1.1 – 4.9)), and ahistory of pneumonia (OR 3.2 (95% CI 1.1 – 8.9)) were higher than in control group. The PSG analysis revealed that severe OSA was detected in mostpatients (52%) of the main group and in none of the patients in the control group. Duration of SpO 2 < 90% was longer in the main group (42.4 min), than in the control group (0.9 min). The apnea-hypopnea index was increased in the REM sleep stage and in supine position in the main group. Duration of sleep stages was different: stage 1 was longer in the main group and stage 2 was longer in the control group. There were no differences in REM and stage 3. Obese patients had more frequent arousals, due to episodes of apnea and hypopnea and snoring. Conclusion . Our study identified certain characteristics of PSG in OSA and obesity, which may explain the higher incidence of concomitant severe diseases that may be associated with cardio-renal-metabolic syndrome.

  • Open Access

    Pulmometabolic syndrome: a review

    by Tatiana A. Bakhareva, Alexander M. Belov, Stanislav D. Gorbunkov, Arthur I. Yusupov, Irina A. Baranova, Бахарева Татьяна Александровна, Юсупов Артур Ильдусович

    In this review, we discuss the underexplored issue of the relationship between metabolic syndrome (MS) and respiratory diseases. The review discusses the main pathogenic mechanisms, including chronic low-grade inflammation, oxidative stress, endothelial dysfunction, and mechanical restriction of lung volumes. The concept of pulmonometabolic syndrome is introduced. Data of the results of studies of the functional parameters of the lungs in MS are presented. We describe the clinical and pathobiological characteristics of the mutually aggravating interaction between MS and respiratory disorders, such as chronic obstructive pulmonary disease, bronchial asthma, obstructive sleep apnea, lung cancer, and pulmonary hypertension.

  • Open Access

    Rehabilitation program of post-COVID-19 syndrome with the use of nitric oxide and molecular hydrogen

    by D D Pozdnyakova, T А Bakhareva, I A Baranova, V D Selemir, A G Chuchalin

    Рost-COVID-19 syndrome (PS) is one of the medical and social problem. According to WHO, 10–20% of COVID-19 patients suffer from PS. The use of medical gases – inhaled nitric oxide (iNO) and molecular hydrogen (iH2) – may influence on the mechanisms of development PC. Aim. To evaluate the safety and efficacy of the combined inhalation of NO and H2 (iNO/iH2) in patients with respiratory manifestations of PS. Materials and methods. 34 patients with PS (11 men/23 women, 60.0±11.7 years) were included in the prospective open-label controlled study in parallel groups: the main group (n=17) received iNO/iH2 for 90 minutes once a day for 10 days (concentration of NO 60 ppm, H24% in the gas mixture), the control group (n=17) didn’t receive inhalations. The period from the confirmation of COVID-19 to the start of the study was 641.8±230.5 days. The groups did not differ in the baseline parameters. The clinical symptoms (from the self-observation diary and mMRC questionnaires, "dyspnea language"), FAS, HADS, SF-36 scores, 6-minute walk test, the blood serum parameters of oxidative stress, the dynamics of the microcirculation in the eye bulbar conjunctiva were evaluated. The individual dose of iNO has chosen during a 15-minute test (the positive dynamics of the microcirculation have indicated that the dose was selected correctly). Results. The decrease the symptoms severity, such as dyspnea, cough, fatigue and palpitations (p0.005), the increase in SF-36 questionnaire scores (p=0.006) and a reducing of FAS score (p=0.001), as well as the anxiety component of HADS (p=0.02) were revealed at the end of treatment in the main group compared to the control group. We observed an improvement in distance walked (p=0.01) and the values SpO2 (p=0.04) in 6-minute walk test, the increase in the volumetric blood flow velocity in venules (p0.001), and the date in oxidative damage (p0.001) and antioxidant activity (p=0.03) parameters in the blood serum. Conclusion. The results of the study demonstrate clinical efficacy iNO/iH2 on clinical indicators, parameters of oxidative stress and microcirculation in patients with PS.